Hilary Kramer

Hilary Kramer

Hilary Kramer is one of Wall Street’s most successful equity analysts and investment managers, with a reputation as a leading expert on today’s market movements, stock trends and economic outlook.

She received her MBA from the Wharton School at the University of Pennsylvania and her BA from Wellesley College with honors. Hilary Kramer got her start on Wall Street more than two decades ago at Lehman Brothers and Morgan Stanley where she was an analyst in the investment banking group covering natural resources, diversified industrials and energy companies. She was also the chief investment officer of a family office — overseeing a $5.2 billion global private equity and publicly-traded equity fund, and co-vice chairman of the $500 million Ibero-American Partners Fund (1997 to 2003).

In 2004, Hilary’s A&G Capital formed a specialized research arm and investment fund. The GreenTech 21st Century Master Fund focused on companies engaged in alternative energy, clean technologies, environmental infrastructure and services, agricultural and natural resources.

Today, Hilary Kramer is an in-demand commentator whose work often appears in investing publications such as the Wall Street Journal, New York Post, Bloomberg, Business Insider and Reuters and is a regular on CNBC, CNN and the Fox News Channel, providing stock market insight and economic observations.

Hilary Kramer is also the editor of several financial advisory services designed to help individual investors profit from her stock picking talents: Value Authority, GameChangers, Breakout Stocks, High Octane Trader, Absolute Capital Return, Inner Circle and Inner Circle Pro.

Recent Articles

9 GameChangers That Will Affect Your Money in 2011

2011 looks positive for the major indices, commodities, China, and natural gas and biotech stocks, says market expert Hilary Kramer.

Evercore (EVR) Stock An M&A GameChanger in 2011

Evercore NYSE:EVR is poised for big growth in 2011 as it benefits from increased merger and acquisition business.

Two of the Best Opportunities in Biotech

If you're looking for biotech stocks to buy, Hilary Kramer advises looking at potential takeover targets SHPGY and DNDN.

5 Reasons to Avoid the GM IPO

Investors should avoid GM's IPO for several reasons, including its unstable management and shrinking market share.

5 Reasons to Buy Ford Now

Investors should focus on a newly-revitalized Ford instead of the GM IPO.